The Pharmaceutical Research Shared Resource, consisting of an Investigational Chemotherapy Service and a Cancer Clinical Pharmacology Laboratory, provides a broad range of services to support the conduct of clinical hematology/oncology research. The Investigafional Chemotherapy Service (ICS) is available to all Duke Cancer Institute investigators for the purpose of maintaining drug accountability records and investigafional drug Inventories according to FDA and CTEP guidelines. In addition, this resource provides design consultafion, professional staff educafion, and implementafion services for clinical research studies. The primary focus ofthe Clinical Pharmacology Lab (GPL) is to invesfigate the pharmacokinefics and pharmacodynamics of anticancer drugs and recombinant proteins used in the experimental therapy of cancer. This resource is also available for analysis of endogenous cytokine concentrations during investigational therapy. One of the major goals of the laboratory is to identify predictors of resppnse and toxicity and implement methods to reduce inter-patient variability and drug exposure. The lab provides both consultative and analytic services regarding clinical pharmacokinetic studies of anticancer compounds and recombinant proteins. These include: aid with trial design, opfimal sampling techniques, sample handling and stability, quantitative measurement of drug and metabolite concentrafions (via HPLC, atomic absorpfion spectrophotometry, gas chromatography/mass spectrophotometry, or ELISA), calculation of individual and populafion pharmacokinetic parameters and pharmacometric evaluafion via sophisficated computer modeling programs. This resource has maintained a high level of usage by Duke Cancer Institute investigators including those from the Experimental Therapeutics Program, Breast arid Ovarian Oncology, Hematopoietic Transplantafion and Hematologic Malignancies, Neuro-Oncology, Radiation, and Cancer Biology Programs.

Public Health Relevance

(

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-40
Application #
8601849
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
40
Fiscal Year
2014
Total Cost
$85,331
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Adams, Rebecca N; Mosher, Catherine E; Blair, Cindy K et al. (2015) Cancer survivors' uptake and adherence in diet and exercise intervention trials: an integrative data analysis. Cancer 121:77-83
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650-6
Batinic-Haberle, Ines; Tovmasyan, Artak; Roberts, Emily R H et al. (2014) SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal 20:2372-415
Sachdeva, Mohit; Mito, Jeffrey K; Lee, Chang-Lung et al. (2014) MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest 124:4305-19
Tovmasyan, Artak; Carballal, Sebastian; Ghazaryan, Robert et al. (2014) Rational design of superoxide dismutase (SOD) mimics: the evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents. Inorg Chem 53:11467-83
Azrad, Maria; Demark-Wahnefried, Wendy (2014) The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Curr Nutr Rep 3:9-15
Blair, Cindy K; Madan-Swain, Avi; Locher, Julie L et al. (2013) Harvest for health gardening intervention feasibility study in cancer survivors. Acta Oncol 52:1110-8
Mito, Jeffrey K; Min, Hooney D; Ma, Yan et al. (2013) Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol 229:132-40
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2013) Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol 40:52-9
Hover, Bradley M; Loksztejn, Anna; Ribeiro, Anthony A et al. (2013) Identification of a cyclic nucleotide as a cryptic intermediate in molybdenum cofactor biosynthesis. J Am Chem Soc 135:7019-32

Showing the most recent 10 out of 161 publications